Cytokinetics CYTK Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's investing cash flow?
- Cytokinetics (CYTK) reported investing cash flow of $145.49M in Q1 2026.
- How has Cytokinetics's investing cash flow changed year-over-year?
- Cytokinetics's investing cash flow increased by 37.3% year-over-year, from $105.96M to $145.49M.
- What does investing cash flow mean?
- The net cash impact of buying and selling assets and investments.
- How do you interpret investing cash flow?
- Positive values often indicate the liquidation of investments to fund operations, while negative values suggest the deployment of cash into investments or infrastructure.
- How does investing cash flow compare across companies?
- Highly variable for biotech firms depending on whether they are in a cash-burning phase or a cash-preservation phase.